Leonard Abramson Dies at 93 After Building U.S. Healthcare and Giving Away Nearly $1 Billion
Updated
Updated · The New York Times · Jul 14
Leonard Abramson Dies at 93 After Building U.S. Healthcare and Giving Away Nearly $1 Billion
1 articles · Updated · The New York Times · Jul 14
Summary
July 4 marked the death of Leonard Abramson at his home in Blue Bell, Pennsylvania; the former pharmacist was 93, and his daughter Judith Abramson Felgoise confirmed it.
Abramson built U.S. Healthcare into one of the first major health maintenance organizations, launching it two years after the 1973 HMO Act encouraged new models to curb rising medical costs.
U.S. Healthcare helped pioneer a more open, rapidly expandable HMO structure and was among the first to shift from nonprofit to for-profit status, a model other insurers later followed.
Nearly $1 billion from the sale of the company later funded Abramson's philanthropy, including major support for cancer research and other medical causes.
Does a billion dollars in medical philanthropy justify a business model often criticized for prioritizing profits over patient well-being?
Did the for-profit HMO model, intended to reduce healthcare costs, ultimately make the system more expensive and less effective for patients?
Leonard Abramson’s Dual Legacy: Transforming U.S. Healthcare with an $8.9 Billion Sale and $140 Million in Medical Philanthropy
Overview
Leonard Abramson, who passed away on July 4, 2026, was a respected leader in Philadelphia and a key figure in American healthcare. Known for his quiet leadership style, he helped shape the managed healthcare industry and earned deep respect from his peers. Alongside his wife Madlyn, Abramson built a powerful philanthropic legacy, funding endowed professorships and supporting major research and care programs, especially in oncology. His dual impact as both a pioneering healthcare executive and a generous philanthropist continues to influence medical research and patient care, marking the end of an era and ensuring his legacy endures.